AmorChem spins out Corbin Therapeutics, invests $1 mln
AmorChem has launched Corbin Therapeutics Inc, a drug discovery platform to identify and develop novel USP15 inhibitors for treatment of inflammation diseases, such as multiple sclerosis. Corbin, AmorChem's third spin-off company, was also provided with $1 million in seed-stage financing. Maxime Ranger was appointed the Montréal-based startup's CEO, while Dr Philippe Gros, who researched the USP15 technology, was named its scientific advisor. AmorChem, which is managed by Canadian life sciences venture capital firm GeneChem, spun out and financed another company, Mperia Therapeutics Inc, last September.
11 January 2017•4 mins read
